Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Naoki Ikenaga, Zhen Wei Peng, Kahini A. Vaid, Susan B. Liu, Shuhei Yoshida, Deanna Y. Sverdlov, Amanda Mikels-Vigdal, Victoria Smith, Detlef Schuppan, Yury V. Popov

Research output: Contribution to journalArticle

104 Citations (Scopus)

Fingerprint Dive into the research topics of 'Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal'. Together they form a unique fingerprint.

Medicine & Life Sciences